Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.900
+0.020 (1.06%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
+0.040 (2.11%)
After-hours: Apr 28, 2026, 6:03 PM EDT
Acrivon Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 24.12 | 25.21 | 21.08 | 8.71 | 2.47 | |
| Research & Development | 59.99 | 63.99 | 46.02 | 23.95 | 13.72 | |
| Operating Expenses | 84.11 | 89.2 | 67.1 | 32.66 | 16.18 | |
| Operating Income | -84.11 | -89.2 | -67.1 | -32.66 | -16.18 | |
| Interest & Investment Income | 6.48 | 9.2 | 7.04 | - | - | |
| Currency Exchange Gain (Loss) | 0.2 | -0.1 | - | - | - | |
| Other Non Operating Income (Expenses) | -0.91 | -4.24 | -3.65 | 0.79 | -0.06 | |
| EBT Excluding Unusual Items | -78.34 | -84.33 | -63.71 | -31.87 | -16.24 | |
| Gain (Loss) on Sale of Investments | 0.44 | 3.78 | 3.32 | 0.7 | - | |
| Pretax Income | -77.91 | -80.56 | -60.39 | -31.17 | -16.24 | |
| Net Income | -77.91 | -80.56 | -60.39 | -31.17 | -16.24 | |
| Net Income to Common | -77.91 | -80.56 | -60.39 | -31.17 | -16.24 | |
| Shares Outstanding (Basic) | 39 | 34 | 22 | 4 | 2 | |
| Shares Outstanding (Diluted) | 39 | 34 | 22 | 4 | 2 | |
| Shares Change (YoY) | 13.96% | 53.05% | 435.63% | 136.43% | 21.70% | |
| EPS (Basic) | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 | |
| EPS (Diluted) | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 | |
| Free Cash Flow | -65.33 | -68.44 | -43.93 | -32.28 | -14.22 | |
| Free Cash Flow Per Share | -1.70 | -2.02 | -1.99 | -7.83 | -8.16 | |
| EBITDA | -82.76 | -88.19 | -66.57 | -32.29 | -16.15 | |
| D&A For EBITDA | 1.36 | 1.01 | 0.54 | 0.36 | 0.04 | |
| EBIT | -84.11 | -89.2 | -67.1 | -32.66 | -16.18 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.